Insomnia: Contemporary Perspectives {#section1-1179573518770672}
===================================

The conceptualization of insomnia as a clinical disorder has evolved considerably in recent decades. This is reflected in the numerous nosology revisions which have occurred in this time and which are currently represented in the *International Classification of Sleep Disorders* (Third Edition; *ICSD-3*) and the *Diagnostic and Statistical Manual of Mental Disorders* (Fifth Edition; *DSM-5*).^[@bibr1-1179573518770672],[@bibr2-1179573518770672]^ These contemporary diagnostic approaches employ broad definitions of insomnia disorders that avoid the shortcomings found in previous versions, such as the use of multiple subtypes, specific developmental disorder categories, and attempts to differentiate primary, secondary, or comorbid insomnia. The ICSD-3 includes 2 insomnia disorders (chronic and short-term) plus an "other" category for provisional use before a final diagnosis is established.^[@bibr1-1179573518770672]^ Chronic and short-term insomnia disorders have similar criteria with the exception of the duration of symptoms (ie, longer or shorter than 3 months). Essential features of insomnia include difficulty initiating sleep, difficulty maintaining sleep, waking up earlier than desired, resistance to going to bed on an appropriate schedule, or difficulty sleeping without parent or caregiver intervention. Required sleep difficulty associations include the following: fatigue or malaise; impairment in attention, concentration, or memory; social, family, vocational, or academic performance impairment; mood disturbance or irritability; daytime sleepiness; behavioral problems such as hyperactivity, impulsivity, and aggression; decreased motivation, energy, and initiative; proneness for errors and accidents; or dissatisfaction or concerns about sleep. The number of sleep difficulty associations varies with each patient and the course of the insomnia disorder. The sleep and wake complaints must not be attributable to inadequate circumstances or opportunity for sleep, nor should they be better explained by another sleep disorder.

Difficulty with sleep onset and sleep maintenance is the most common sleep-related complaint encountered in primary care and many medical specialty practices. General population prevalence estimates vary depending on specific survey questions. Naturally, broad questions about sleep complaints result in relatively high prevalence rates, whereas more narrow questions representing diagnostic criteria find much lower rates. Studies typically estimate that approximately one-third of adults experience at least one insomnia symptom. Nighttime sleep difficulty along with daytime impairment is reported by about 10% to 15% of the population. The insomnia disorder criteria are satisfied in 6% to 10% of adults. Women have increased risk for insomnia compared with men with a ratio of 1.44. Older individuals also have a greater likelihood of sleep difficulty. Finally, people with comorbid psychiatric and medical conditions are at greater risk for having insomnia symptoms.^[@bibr2-1179573518770672]^

The plan for treating chronic insomnia patients should evolve from a comprehensive evaluation that considers the history of the sleep-related symptoms; the presence of additional sleep, medical, and psychiatric disorders; past treatment effects; concurrent medications; treatment availability; and patient preference.^[@bibr2-1179573518770672]^ The treatment of insomnia may include combinations of healthy sleep habit recommendations, psychological, and behavioral strategies (eg, cognitive behavioral therapy); timed exposure to bright light or darkness; and the use of assorted pharmacologic agents. The American Academy of Sleep Medicine has published guidelines regarding the pharmacologic treatment of insomnia in adults.^[@bibr3-1179573518770672],[@bibr4-1179573518770672]^ Key recommendations include the incorporation of behavioral and psychotherapeutic strategies along with the use of medications. Choices regarding medication selection should be based on the patient's sleep-related symptoms during the nighttime and daytime, any comorbid conditions, sex, reproductive status, age, work or school schedules, and lifestyle routines. Of course, the potential for drug-drug interactions must be reviewed. Patients should be monitored regularly for the safety and efficacy of recommended medications. Generally, lower doses should be employed with elderly patients and others with debilitating medical conditions.^[@bibr3-1179573518770672]^

Insomnia Pharmacotherapy {#section2-1179573518770672}
========================

The current generation of medications approved for the treatment of insomnia includes a wide diversity of compounds differing in their pharmacodynamic and pharmacokinetic characteristics. Overall, these represent a major advance in safety compared with historic pharmacologic classes (eg, barbiturates) employed for insomnia. The domain of substances that people take with the intention of helping them sleep more effectively can be divided into 4 broad categories based on whether there is an approved indication for insomnia treatment or as a sleep aid, and whether access to the medication requires a prescription. The resulting grid ([Figure 1](#fig1-1179573518770672){ref-type="fig"}) yields these groups of compounds: (1) regulatory agency (eg, US Food and Drug Administration) approved prescription-required medications, (2) prescription-required medications without insomnia treatment indications that are recommended on an "off-label" basis for possible sleep-enhancing effects, (3) regulatory agency approved over-the-counter (OTC) products, and (4) unregulated dietary supplements marketed for sleep enhancement. Not surprisingly, the efficacy evidence is strongest for the regulatory agency--approved insomnia medications and weakest for the unregulated dietary supplements (with the exception of selected uses of melatonin).^[@bibr5-1179573518770672]^

![Categories of compounds that people take to try to treat insomnia based on indication and requirement for prescription. FDA indicates Food and Drug Administration.](10.1177_1179573518770672-fig1){#fig1-1179573518770672}

This review of medications and other substances that people take with the intention of improving their sleep represents a top-down approach. That is, the discussion focuses on pharmacologic features of those compounds that have been approved for the treatment of insomnia or otherwise are commonly employed for this purpose. The goal is to highlight the wide diversity of insomnia remedies and to review data that may aid in clinical decision making. Often treatment selections are based on advertising, word of mouth, and tradition, rather than pharmacodynamic and pharmacokinetic properties. The medications with regulatory approval for insomnia treatment all have been comprehensively evaluated for their efficacy and safety characteristics in populations of healthy individuals and subjects with insomnia. In contrast, very limited efficacy and safety evidence is available for the other medications and substances when used to treat insomnia.

The domain of this discussion is compounds available in the United States. An international catalog of all available insomnia medications would be beyond the scope of this article. Fortunately, most of the products licensed for insomnia treatment elsewhere also are marketed in the United States. The primary exceptions are selected benzodiazepine receptor agonist (BZRA) hypnotics for which review in this article remains relevant.

Medications Approved for the Treatment of Insomnia {#section3-1179573518770672}
==================================================

The medications approved for treating insomnia represent 4 fundamental pharmacodynamic categories with key actions related to receptors for γ-aminobutyric acid (GABA), melatonin, histamine, or orexin/hypocretin. All are based on well-established neurotransmitter effects on sleep and waking.^[@bibr6-1179573518770672]^ These medications all have been evaluated for efficacy and safety in placebo-controlled clinical trials with populations of insomnia subjects. Some medications improve sleep onset or sleep maintenance, whereas others improve both variables, typically consistent with their pharmacokinetic parameters.

The common side effects, contraindications, pregnancy category, and predictable drug-drug interactions are highlighted in the prescribing information. Most of the approved hypnotics in the United States are classed as Schedule IV controlled substances due to some degree of abuse potential, although 2 (doxepin and ramelteon) are considered unscheduled because of their absence of risk for abuse. These features are detailed in [Tables 1](#table1-1179573518770672){ref-type="table"} to [3](#table3-1179573518770672){ref-type="table"}. Broad warnings for hypnotic medication include the potential for rare allergic reactions and for complex sleep-related behaviors.^[@bibr6-1179573518770672]^

###### 

Medications Approved by the U.S. Food and Drug Administration for the Treatment of Insomnia.

![](10.1177_1179573518770672-table1)

  Generic name                                    Brand Name   Available Doses (mg)   Elimination Half-life (hr)
  ----------------------------------------------- ------------ ---------------------- ---------------------------------
  ***BENZODIAZEPINE RECEPTOR AGONISTS***                                              
  ***Benzodiazepine Immediate Release***                                              
  Estazolam                                       ProSom       1, 2                   10 - 24
  Flurazepam                                      Dalmane      15, 30                 2.3/48 -- 160 active metabolite
  Quazepam                                        Doral        7.5, 15                39/73 active metabolite
  Temazepam                                       Restoril     7.5, 15, 22.5, 30      3.5 -- 18.4
  Triazolam                                       Halcion      0.125, 0.25            1.5 -- 5.5
  ***Nonbenzodiazepine Immediate Release***                                           
  Eszopiclone                                     Lunesta      1, 2, 3                6/ 9 in elderly
  Zaleplon                                        Sonata       5, 10                  1
  Zolpidem                                        Ambien       5, 10                  2.8 in males
  ***Nonbenzodiazepine Extended Release***                                            
  Zolpidem ER                                     Ambien CR    6.25, 12.5             1.6 -- 4.5
  ***Nonbenzodiazepine Alternate Delivery***                                          
  Zolpidem oral spray                             Zolpimist    5, 10                  2.7 -- 3.0
  Zolpidem sublingual                             Edluar       5, 10                  \~2.5
  Zolpidem sublingual                             Intermezzo   1.75, 3.5              \~2.5
  ***SELECTIVE MELATONIN RECEPTOR AGONIST***                                          
  Ramelteon                                       Rozerem      8                      1 -- 2.6
  ***SELECTIVE HISTAMINE RECEPTOR ANTAGONIST***                                       
  Doxepin (low dose)                              Silenor      3, 6                   15.3
  ***DUAL OREXIN RECEPTOR ANTAGONIST***                                               
  Suvorexant                                      Belsomra     5, 10, 15, 20          12

###### 

Approved indications for US insomnia medications.

![](10.1177_1179573518770672-table2)

  Medication                   Unspecified insomnia   Sleep onset   Sleep maintenance   Early awakening
  ---------------------------- ---------------------- ------------- ------------------- -----------------
  Estazolam                                           ✓             ✓                   ✓
  Flurazepam                                          ✓             ✓                   ✓
  Quazepam                                            ✓             ✓                   ✓
  Temazepam                    ✓                                                        
  Triazolam                    ✓                                                        
  Eszopiclone                                         ✓             ✓                   
  Zaleplon                                            ✓                                 
  Zolpidem                                            ✓                                 
  Zolpidem ER                                         ✓             ✓                   
  Zolpidem spray                                      ✓                                 
  Zolpidem sublingual                                 ✓                                 
  Zolpidem sublingual---MOTN                                        ✓                   
  Ramelteon                                           ✓                                 
  Low-dose doxepin                                                  ✓                   
  Suvorexant                                          ✓             ✓                   

Abbreviation: MOTN, middle of the night.

###### 

Drug Enforcement Administration (DEA) class, pregnancy category (PC), and most common side effects for US insomnia medications.

![](10.1177_1179573518770672-table3)

  Medication                 DEA class   PC   Most common side effects
  -------------------------- ----------- ---- -------------------------------------------------------------------------------------------------------------------------------
  Estazolam                  IV          X    Somnolence, hypokinesia, dizziness, abnormal coordination
  Flurazepam                 IV          X    Dizziness, drowsiness, lightheadedness, loss of coordination, staggering, falling
  Quazepam                   IV          X    Drowsiness, headache
  Temazepam                  IV          X    Drowsiness, dizziness, lightheadedness, difficulty with coordination
  Triazolam                  IV          X    Drowsiness, headache, dizziness, "pins & needles," coordination difficulty, lightheadedness
  Eszopiclone                IV          C    Unpleasant taste, headache, somnolence, rash, respiratory and viral infections, dizziness, dry mouth, anxiety, hallucinations
  Zaleplon                   IV          C    Drowsiness, lightheadedness, dizziness, "pins & needles," difficulty with coordination
  Zolpidem                   IV          C    Drowsiness, dizziness, diarrhea, drugged feeling
  Zolpidem ER                IV          C    Headache, next-day somnolence, dizziness
  Zolpidem spray             IV          C    Drowsiness, dizziness, diarrhea, drugged feeling
  Zolpidem sublingual        IV          C    Drowsiness, dizziness, diarrhea, drugged feeling
  Zolpidem sublingual-MOTN   IV          C    Headache, nausea, fatigue
  Ramelteon                  ---         C    Somnolence, dizziness, fatigue, nausea, exacerbated insomnia
  Low-dose doxepin           ---         C    Somnolence/sedation, nausea, upper respiratory tract infection
  Suvorexant                 IV          C    Somnolence

Benzodiazepine Receptor Agonists {#section4-1179573518770672}
================================

Hypnotic medications classed as BZRA became available beginning in the 1970s, and at the time they represented a safer alternative to the commonly prescribed barbiturates. The earliest BZRA hypnotics were defined by their characteristic benzodiazepine structure (benzene and diazepine rings); however, the more recent additions to this class have alternate "nonbenzodiazepine" structures. The indications are for insomnia characterized by difficulty with sleep onset, difficulty with sleep onset and sleep maintenance, or middle-of-the-night awakenings with difficulty returning to sleep. The more common side effects associated with BZRA hypnotics include somnolence, dizziness, headache, fatigue, ataxia, anterograde amnesia, and confused behaviors. Rebound insomnia may occur with abrupt discontinuation.

The BZRA hypnotics all are manufactured in immediate-release tablet or capsule formulations, with the exception of zolpidem which is additionally available in an extended-release bedtime use tablet, oral dissolvable doses for bedtime or middle-of-the-night use, and an oral liquid spray formulation.

Pharmacodynamics {#section5-1179573518770672}
----------------

All BZRA hypnotics are positive allosteric modulators of GABA responses at the GABA~A~ receptor complex.^[@bibr7-1179573518770672]^ GABA is the most widespread inhibitory neurotransmitter in the central nervous system (CNS) and also has targeted action in hypothalamic regions involved in the regulation of sleep and wakefulness.^[@bibr8-1179573518770672]^ The GABA~A~ receptor complex is a pentameric transmembrane structure with a central chloride ion channel. When GABA attaches to the GABA recognition site, negative chloride ions are able to enter the cell, a process that hyperpolarizes the cell membrane and decreases the likelihood of an action potential. When a benzodiazepine agonist interacts with a separate benzodiazepine recognition site on the receptor complex, the result is an enhanced influx of chloride ions with a greater inhibitory effect when GABA is present.^[@bibr9-1179573518770672]^

Pharmacokinetics {#section6-1179573518770672}
----------------

The BZRA hypnotics all are relatively rapidly absorbed, so may be beneficial for sleep onset. The hepatic cytochrome P450 (CYP)3A4 pathway is the primary route of metabolism for these medications, although additional CYP isoenzymes or glucuronide conjugation may have significant roles, as with temazepam.^[@bibr10-1179573518770672]^ The elimination half-lives vary considerably and approximately correlate with the duration of action and risk for next-day residual sedation and impairment. Benzodiazepine BZRA medications range from approximately 3.5 hours for triazolam to more than 24 hours for flurazepam and quazepam when active metabolites are included. The nonbenzodiazepine BZRA medications range from 1 hour for zaleplon to approximately 6 to 9 hours for eszopiclone, with zolpidem in between at about 2.5 hours for the basic compound. The finding of a gender effect on zolpidem metabolism characterized by higher area under the curve and peak plasma concentration values in women than men led to the recommendation to reduce by 50% the dosage of some formulations of the hypnotic agent.^[@bibr11-1179573518770672]^

Melatonin Receptor Agonist {#section7-1179573518770672}
==========================

Melatonin is a hormone produced in the pineal gland under control of the circadian system in the hypothalamic suprachiasmatic nucleus (SCN).^[@bibr12-1179573518770672]^ Normally the melatonin level is low throughout the daytime, gradually rises in the evening as bedtime approaches, plateaus during the typical sleep period at nighttime, and then declines by the typical wake time around dawn. The circadian system promotes an arousal signal in the late afternoon and evening which opposes the homeostatic sleepiness accumulating since sleep last occurred, thus allowing alertness during the day and evening. With the later-evening melatonin rise, the circadian arousal level declines, leaving the homeostatic sleep drive unopposed. In this manner, the melatonin rise facilitates sleep onset and additionally reinforces the timing of the circadian system.^[@bibr4-1179573518770672]^

In the United States, ramelteon is the only melatonin receptor agonist indicated for the treatment of insomnia.^[@bibr13-1179573518770672]^ This agent has a specific indication for difficulty with sleep onset. It has no abuse potential. In the United States, melatonin itself is an unregulated dietary supplement, although in the European Union, an extended-release melatonin formulation is available only by prescription.^[@bibr14-1179573518770672]^ Tasimelteon also is a melatonin receptor agonist, although it is indicated for the treatment of non--24-hour circadian rhythm sleep-wake disorder.^[@bibr15-1179573518770672]^ Agomelatine, marketed as an antidepressant and not currently available in the United States, has multiple receptor effects that include melatonin receptor agonist activity.^[@bibr16-1179573518770672]^

Pharmacodynamics {#section8-1179573518770672}
----------------

Ramelteon is a selective agonist for the MT1 and MT2 melatonin receptors that are highly represented in the SCN.^[@bibr17-1179573518770672]^ Accordingly, ramelteon may enhance sleep onset by decreasing the evening circadian arousal and may also help stabilize the timing of the sleep-wake cycle.

Pharmacokinetics {#section9-1179573518770672}
----------------

The time to maximum concentration (*C*~max~) for ramelteon is approximately 0.75 hour in the fasted state. Metabolism is primarily through CYP1A2, and to a limited extent through CYP2C and CYP3A4. Adjustments may be necessary for inducers and inhibitors for these pathways. A specific contraindication is stated for coadministration of ramelteon with fluvoxamine, a potent CYP1A2 inhibitor. The ramelteon elimination half-life is 1 to 2.6 hours and is about 2 to 5 hours for M-II, a less potent active metabolite.^[@bibr18-1179573518770672]^

Histamine Receptor Antagonist {#section10-1179573518770672}
=============================

Low-dose doxepin is the histamine H~1~ receptor antagonist approved for the treatment of insomnia with a specific indication for difficulty with sleep maintenance.^[@bibr19-1179573518770672]^ While prescribing guidelines for doxepin as an antidepressant goes as high as 300 mg daily and the largest pill strength is 150 mg, the approved insomnia doses are merely 3 and 6 mg. Doxepin should not be coadministered with monoamine oxidase inhibitors.

Pharmacodynamics {#section11-1179573518770672}
----------------

Histamine is a potent wake-promoting neurotransmitter produced in the brain in the tuberomammillary nuclei of the hypothalamus. Antagonists at the H~1~ receptor have sedating properties. Doxepin is very highly selective for the H~1~ receptor and at very low doses has minimal additional pharmacodynamic activity. During the usual nighttime sleep period, wake-promoting neurotransmitters typically are quiescent; however, histamine remains active to a limited extent so may be targeted for antihistaminic action to promote a sedating effect at these low doses, particularly during the latter part of the nighttime.^[@bibr20-1179573518770672]^

Pharmacokinetics {#section12-1179573518770672}
----------------

The time to *C*~max~ for low-dose doxepin is 3.5 hours. CYP2C19 and CYP2D6 are the primary metabolic pathways. The elimination half-life is 15.3 hours.^[@bibr19-1179573518770672]^

Orexin/Hypocretin Receptor Antagonist {#section13-1179573518770672}
=====================================

The orexin/hypocretin system, discovered by 2 independent research groups in 1998, includes 2 similar neuropeptides (orexin A and orexin B) and 2 receptors (OX1R and OX2R) with overlapping distributions.^[@bibr21-1179573518770672],[@bibr22-1179573518770672]^ Orexin/hypocretin-producing neurons in the perifornical lateral hypothalamic region have projections to the cerebrum and to numerous nuclei producing wake-promoting neurotransmitters with a net effect of enhancing and stabilizing the waking state. It is notable that narcolepsy is associated with decreased orexin/hypocretin activity.^[@bibr23-1179573518770672]^ The single currently approved orexin/hypocretin receptor antagonist is suvorexant, although other compounds are being investigated. The indication is for the treatment of insomnia characterized by difficulty with sleep onset and/or sleep maintenance. The presence of narcolepsy is a contraindication.^[@bibr24-1179573518770672]^

Pharmacodynamics {#section14-1179573518770672}
----------------

Suvorexant promotes sleep by decreasing orexin/hypocretin-associated CNS arousal. It functions as a reversible dual (OX1R and OX2R) receptor antagonist.^[@bibr25-1179573518770672]^ The mechanism of action targets a region of the hypothalamus critical for the regulation of sleep and waking and therefore may avoid more global CNS effects. This approach may offer additional daytime benefits for insomnia patients characterized as having symptoms of hyperarousal.

Pharmacokinetics {#section15-1179573518770672}
----------------

Suvorexant is manufactured as an immediate-release tablet. The median time to *C*~max~ under fasting conditions is 2 hours, although there is considerable variability among individuals, and there may be a delay following a high-fat meal. Metabolism is primarily through the CYP3A pathway with limited contribution from CYP2C19. Dosage adjustments may be necessary for CYP3A inducers and inhibitors. The elimination half-life is approximately 12 hours.^[@bibr24-1179573518770672]^

Alternate Medications Prescribed for Sleep {#section16-1179573518770672}
==========================================

As noted above, numerous neurotransmitters have been identified as having wake- or sleep-promoting properties.^[@bibr6-1179573518770672]^ For example, acetylcholine, norepinephrine, serotonin, dopamine, glutamate, and orexin/hypocretin tend to be wake promoting, whereas GABA and galanin are sleep promoting. Adenosine appears to be associated with the homeostatic sleep drive.^[@bibr26-1179573518770672]^ In humans, melatonin facilitates sleep onset during certain circadian periods. Therefore, compounds functioning as agonists or antagonists have the potential to influence sleep and waking, possibly with desired or undesired consequences. It should be noted that medications may have multiple effects and sometimes incorporate both wake- and sleep-promoting actions simultaneously. Most medications prescribed "off label" for insomnia have not been evaluated for either efficacy or safety and have not been studied in subjects with insomnia. Among the noninsomnia--indicated medications sometimes prescribed primarily for sleep enhancement are antidepressants (eg, trazodone, amitriptyline, and mirtazapine), anxiolytics (eg, alprazolam and clonazepam) antipsychotics (eg, quetiapine), and antihypertensives (eg, clonidine). The ideal situation is when a patient with insomnia also has a comorbid condition for which the medication is indicated, as might be the case with mirtazapine for a depressed individual or quetiapine for someone treated for schizophrenia.^[@bibr3-1179573518770672]^ Unfortunately, little evidence is available to guide the use of these medications in the treatment of insomnia.^[@bibr4-1179573518770672]^ Excessive sedation is a common side effect among these medications, as many have relatively long elimination half-lives, but each of the drugs has specific potential adverse effects that must be considered when prescribed for insomnia.

OTC Sleep Aids {#section17-1179573518770672}
==============

By definition, OTC products are available without a prescription but are subject to regulatory agency approval for their doses, manufacture, indications, and marketing. These medications are antihistamines, primarily diphenhydramine and doxylamine.

Although the sleep-promoting pharmacodynamic effect of an antihistamine is predictable, additional receptor effects at recommended doses may lead to adverse effects. Antagonist activity at the acetylcholine muscarinic receptor may be associated with confusion, delirium, dry mouth, constipation, and urinary retention.^[@bibr27-1179573518770672]^ Elderly individuals and people concomitantly taking other medications with anticholinergic properties are the most vulnerable to these effects. With initial use, the OTC antihistamine sleep aids may offer benefits to sleep onset and sleep maintenance. Tolerance for the sleep-promoting effects of these products is possible, and for this reason, some individuals may increase the dose beyond the recommended amounts.^[@bibr28-1179573518770672]^ The elimination half-lives of these products are moderately long and may contribute to next-morning grogginess following bedtime use.

Dietary Supplements Marketed for Sleep {#section18-1179573518770672}
======================================

These compounds are essentially unregulated, though are limited in the extent to which they can be marketed with specific health claims. Products within this category may be marketed as sleep aids. Often they are considered to be in the realm of complementary and alternative or homeopathic medicine. In the United States, there are 2 major categories: (1) melatonin and (2) everything else. There is minimal evidence supporting the use of melatonin at bedtime for the treatment of insomnia.^[@bibr29-1179573518770672],[@bibr30-1179573518770672]^ However, there is considerable evidence for the efficacy of melatonin in the treatment of selected circadian rhythm sleep-wake disorders, for which insomnia often is a key symptom.^[@bibr31-1179573518770672],[@bibr32-1179573518770672]^ It is difficult to generalize about the remarkably diverse assortment of other sleep aid products that contain one or more ingredients derived from plants or minerals and sometimes melatonin as well. Among the common ingredients are valerian, kava-kava, hops, lavender, skullcap, chamomile, and magnesium. The evaluation of these products is complicated by the multitude of molecules in many of the plant extracts. There is no strong evidence supporting the efficacy of these sleep aids, although typically they are regarded as safe, with the exception of kava-kava, for which there have been warnings regarding hepatic failure.^[@bibr33-1179573518770672],[@bibr34-1179573518770672]^

Conclusions {#section19-1179573518770672}
===========

A diverse array of substances is used in the attempt to treat insomnia. Regulatory agencies have approved medications in 4 distinct pharmacodynamic classes with indications for insomnia treatment, in some cases specifically for sleep onset, sleep maintenance, middle-of-the-night awakenings, or early morning awakenings. The assortment of hypnotic medications with different pharmacodynamic and pharmacokinetic properties allows a personalized approach to insomnia pharmacotherapy. Each option is associated with particular risks and benefits. Alternate treatment strategies additionally may include the "off-label" use of other sedating prescription-required medications. People also may turn to OTC antihistamine or unregulated dietary sleep aids, although there is limited support for the use of these products in treating insomnia. Clearly there is a need for further preclinical research on the regulation of sleep and wakefulness, as well as the pathophysiology of insomnia, that will guide the clinical development of new compounds for the safe and effective treatment of this very common disorder.
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